Chronic inflammation plays a critical role in the onset and progression of diabetes, highlighting the role of inflammation and the immune system in diabetes. In type 1 diabetes, autoimmune destruction of pancreatic beta cells results from dysregulated immune responses, while in type 2 diabetes, low-grade systemic inflammation contributes to insulin resistance. Pro-inflammatory cytokines such as TNF-α and IL-6 disrupt insulin signaling pathways, exacerbating metabolic dysfunction. Emerging therapies targeting inflammatory pathways, including immune-modulating drugs and anti-inflammatory diets, offer new possibilities for intervention. Research continues to explore how immune modulation can delay disease onset and improve long-term outcomes in diabetes management.
Title : Does winter melon (Benincasa hispida) improves nutritional values and ameliorating glycaemic parameters
Wan Rosli Wan Ishak, Universiti Sains Malaysia, Malaysia
Title : The menopausal mind: Reframing female senescence as a neuroendocrine disorder with root cause management strategies
Amy Gutman, AdventHealth; Tough Love MD, United States
Title : Diabetes reduction (pre diabetes and type 2) with integrative medicine
F Buck Willis, Christian College of Medicine, Belize
Title : Adipose MTP deficiency protects against hepatic steatosis by upregulating PPAR activity
Sujith Rajan, NYU Long Island School of Medicine, United States
Title : AI receptor binding studies reveal GPR146 conformational states across diabetic phenotypes: Analysis of C peptide and insulin interactions in cholesterol metabolism cortisol regulation and the vitamin D renin angiotensin axis
David Petch, utR Biotech, Canada
Title : Comparative outcomes of antihypertensive therapy in black vs non hispanic white patients with hypertension and cardiovascular disease
Anil Harrison, Midwestern University, United States